Literature DB >> 22606106

7-Chloro-5-(chloro-meth-yl)pyrazolo-[1,5-a]pyrimidine-3-carbonitrile.

Jingli Xu1, Hang Liu, Guixia Li, Chuanmin Qi.   

Abstract

All non-H atoms of the title compound, C(8)H(4)Cl(2)N(4), are essentially coplanar, with an r.m.s. deviation of 0.011 Å. In the crystal, weak C-H⋯N hydrogen bonds link the mol-ecules into infinite sheets parallel to the bc plane.

Entities:  

Year:  2012        PMID: 22606106      PMCID: PMC3344103          DOI: 10.1107/S160053681201166X

Source DB:  PubMed          Journal:  Acta Crystallogr Sect E Struct Rep Online        ISSN: 1600-5368


Related literature

For details of the synthesis, see: Li et al. (2006 ▶). For applications of pyrazolo­[1,5-a]pyrimidines as pharmacophores or building blocks in anti-tumor drug design, see: Li et al. (2006 ▶); Di Grandi et al. (2009 ▶); Powell et al. (2007 ▶); Gopalsamy et al. (2005 ▶).

Experimental

Crystal data

C8H4Cl2N4 M = 227.05 Monoclinic, a = 4.9817 (4) Å b = 18.4025 (15) Å c = 10.1526 (9) Å β = 95.924 (1)° V = 925.78 (13) Å3 Z = 4 Mo Kα radiation μ = 0.66 mm−1 T = 301 K 0.60 × 0.48 × 0.20 mm

Data collection

Bruker SMART APEX CCD area-detector diffractometer Absorption correction: multi-scan (SADABS; Bruker, 2007 ▶) T min = 0.693, T max = 0.879 5429 measured reflections 2111 independent reflections 1749 reflections with I > 2σ(I) R int = 0.017

Refinement

R[F 2 > 2σ(F 2)] = 0.038 wR(F 2) = 0.104 S = 1.04 2111 reflections 127 parameters H-atom parameters constrained Δρmax = 0.46 e Å−3 Δρmin = −0.53 e Å−3 Data collection: SMART (Bruker, 1998 ▶); cell refinement: SAINT (Bruker, 1998 ▶); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 ▶); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 ▶); molecular graphics: SHELXTL (Sheldrick, 2008 ▶); software used to prepare material for publication: SHELXTL. Crystal structure: contains datablock(s) I, global. DOI: 10.1107/S160053681201166X/im2361sup1.cif Structure factors: contains datablock(s) I. DOI: 10.1107/S160053681201166X/im2361Isup2.hkl Supplementary material file. DOI: 10.1107/S160053681201166X/im2361Isup3.cml Additional supplementary materials: crystallographic information; 3D view; checkCIF report
C8H4Cl2N4F(000) = 456
Mr = 227.05Dx = 1.629 Mg m3
Monoclinic, P21/cMo Kα radiation, λ = 0.71073 Å
Hall symbol: -P 2ybcCell parameters from 2237 reflections
a = 4.9817 (4) Åθ = 3.9–27.6°
b = 18.4025 (15) ŵ = 0.66 mm1
c = 10.1526 (9) ÅT = 301 K
β = 95.924 (1)°Block, red
V = 925.78 (13) Å30.60 × 0.48 × 0.20 mm
Z = 4
Bruker SMART APEX CCD area-detector diffractometer2111 independent reflections
Radiation source: fine-focus sealed tube1749 reflections with I > 2σ(I)
Graphite monochromatorRint = 0.017
phi and ω scansθmax = 27.6°, θmin = 2.3°
Absorption correction: multi-scan (SADABS; Bruker, 2007)h = −6→6
Tmin = 0.693, Tmax = 0.879k = −13→23
5429 measured reflectionsl = −12→12
Refinement on F2Primary atom site location: structure-invariant direct methods
Least-squares matrix: fullSecondary atom site location: difference Fourier map
R[F2 > 2σ(F2)] = 0.038Hydrogen site location: inferred from neighbouring sites
wR(F2) = 0.104H-atom parameters constrained
S = 1.04w = 1/[σ2(Fo2) + (0.050P)2 + 0.3703P] where P = (Fo2 + 2Fc2)/3
2111 reflections(Δ/σ)max < 0.001
127 parametersΔρmax = 0.46 e Å3
0 restraintsΔρmin = −0.53 e Å3
Geometry. All e.s.d.'s (except the e.s.d. in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell e.s.d.'s are taken into account individually in the estimation of e.s.d.'s in distances, angles and torsion angles; correlations between e.s.d.'s in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell e.s.d.'s is used for estimating e.s.d.'s involving l.s. planes.
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > σ(F2) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large as those based on F, and R- factors based on ALL data will be even larger.
xyzUiso*/Ueq
Cl10.32935 (9)0.26419 (3)0.40816 (5)0.04533 (17)
Cl20.73176 (14)0.03358 (3)0.13931 (8)0.0784 (3)
N10.9223 (3)0.23861 (8)0.10690 (15)0.0376 (3)
N21.2065 (4)0.41634 (10)−0.0585 (2)0.0636 (5)
N30.5932 (4)0.38077 (9)0.26671 (18)0.0503 (4)
N40.6551 (3)0.31043 (8)0.24035 (15)0.0374 (3)
C10.5553 (4)0.25052 (10)0.29599 (18)0.0363 (4)
C20.6391 (4)0.18420 (10)0.25839 (18)0.0390 (4)
H20.57620.14200.29520.047*
C30.8249 (4)0.18073 (10)0.16175 (18)0.0378 (4)
C40.9331 (5)0.10975 (11)0.1153 (2)0.0554 (6)
H4A1.11090.10180.16150.066*
H4B0.95400.11380.02160.066*
C50.8380 (3)0.30370 (10)0.14617 (17)0.0352 (4)
C60.8930 (4)0.37484 (10)0.11144 (19)0.0423 (4)
C71.0677 (4)0.39787 (10)0.0175 (2)0.0473 (5)
C80.7377 (5)0.41835 (11)0.1879 (2)0.0520 (5)
H80.73620.46880.18370.062*
U11U22U33U12U13U23
Cl10.0409 (3)0.0559 (3)0.0418 (3)−0.0012 (2)0.01678 (19)−0.0018 (2)
Cl20.0764 (4)0.0456 (3)0.1169 (6)−0.0135 (3)0.0270 (4)−0.0184 (3)
N10.0376 (8)0.0389 (8)0.0378 (8)0.0000 (6)0.0108 (6)0.0019 (6)
N20.0747 (13)0.0502 (11)0.0710 (13)−0.0039 (10)0.0321 (11)0.0098 (10)
N30.0591 (11)0.0374 (9)0.0574 (10)0.0019 (8)0.0213 (8)−0.0043 (8)
N40.0381 (8)0.0379 (8)0.0377 (8)−0.0003 (6)0.0110 (6)−0.0009 (6)
C10.0323 (8)0.0449 (10)0.0328 (8)−0.0023 (7)0.0089 (7)0.0012 (7)
C20.0403 (9)0.0381 (10)0.0398 (9)−0.0032 (8)0.0099 (8)0.0035 (8)
C30.0403 (9)0.0364 (9)0.0376 (9)−0.0009 (7)0.0075 (7)0.0007 (7)
C40.0654 (14)0.0379 (11)0.0676 (14)0.0002 (10)0.0292 (11)−0.0003 (10)
C50.0333 (8)0.0391 (9)0.0341 (9)−0.0023 (7)0.0078 (7)0.0007 (7)
C60.0458 (10)0.0368 (10)0.0458 (10)−0.0045 (8)0.0114 (8)0.0033 (8)
C70.0549 (12)0.0360 (10)0.0527 (12)−0.0045 (9)0.0137 (10)0.0047 (9)
C80.0621 (13)0.0350 (10)0.0612 (13)−0.0022 (9)0.0177 (11)−0.0011 (9)
Cl1—C11.7006 (18)C2—C31.418 (2)
Cl2—C41.755 (2)C2—H20.9300
N1—C31.318 (2)C3—C41.507 (3)
N1—C51.343 (2)C4—H4A0.9700
N2—C71.139 (3)C4—H4B0.9700
N3—C81.325 (3)C5—C61.390 (3)
N3—N41.364 (2)C6—C81.402 (3)
N4—C11.356 (2)C6—C71.421 (3)
N4—C51.393 (2)C8—H80.9300
C1—C21.357 (3)
C3—N1—C5117.09 (15)C3—C4—H4A108.6
C8—N3—N4103.25 (16)Cl2—C4—H4A108.6
C1—N4—N3126.15 (15)C3—C4—H4B108.6
C1—N4—C5120.50 (15)Cl2—C4—H4B108.6
N3—N4—C5113.35 (15)H4A—C4—H4B107.5
N4—C1—C2118.49 (16)N1—C5—C6133.52 (16)
N4—C1—Cl1117.07 (14)N1—C5—N4121.99 (15)
C2—C1—Cl1124.44 (14)C6—C5—N4104.50 (15)
C1—C2—C3118.48 (16)C5—C6—C8105.24 (17)
C1—C2—H2120.8C5—C6—C7126.97 (18)
C3—C2—H2120.8C8—C6—C7127.79 (19)
N1—C3—C2123.45 (17)N2—C7—C6179.6 (3)
N1—C3—C4114.14 (16)N3—C8—C6113.67 (19)
C2—C3—C4122.40 (16)N3—C8—H8123.2
C3—C4—Cl2114.86 (15)C6—C8—H8123.2
C8—N3—N4—C1−179.43 (19)C3—N1—C5—C6−179.6 (2)
C8—N3—N4—C50.3 (2)C3—N1—C5—N4−0.2 (3)
N3—N4—C1—C2−179.90 (18)C1—N4—C5—N10.0 (3)
C5—N4—C1—C20.4 (3)N3—N4—C5—N1−179.71 (17)
N3—N4—C1—Cl10.6 (3)C1—N4—C5—C6179.58 (16)
C5—N4—C1—Cl1−179.05 (13)N3—N4—C5—C6−0.1 (2)
N4—C1—C2—C3−0.6 (3)N1—C5—C6—C8179.4 (2)
Cl1—C1—C2—C3178.78 (14)N4—C5—C6—C80.0 (2)
C5—N1—C3—C2−0.1 (3)N1—C5—C6—C70.0 (4)
C5—N1—C3—C4−178.66 (18)N4—C5—C6—C7−179.5 (2)
C1—C2—C3—N10.5 (3)N4—N3—C8—C6−0.3 (3)
C1—C2—C3—C4178.98 (19)C5—C6—C8—N30.2 (3)
N1—C3—C4—Cl2−159.03 (16)C7—C6—C8—N3179.7 (2)
C2—C3—C4—Cl222.4 (3)
D—H···AD—HH···AD···AD—H···A
C8—H8···N2i0.932.503.337 (3)150
C2—H2···N2ii0.932.703.515 (3)146
Table 1

Hydrogen-bond geometry (Å, °)

D—H⋯AD—HH⋯ADAD—H⋯A
C8—H8⋯N2i0.932.503.337 (3)150
C2—H2⋯N2ii0.932.703.515 (3)146

Symmetry codes: (i) ; (ii) .

  5 in total

1.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

2.  Pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as novel antiproliferative agents: exploration of core and headpiece structure-activity relationships.

Authors:  Dennis Powell; Ariamala Gopalsamy; Yanong D Wang; Nan Zhang; Miriam Miranda; John P McGinnis; Sridhar K Rabindran
Journal:  Bioorg Med Chem Lett       Date:  2007-01-13       Impact factor: 2.823

3.  Synthesis and anti-tumor activities of novel pyrazolo[1,5-a]pyrimidines.

Authors:  Juan Li; Yan Fang Zhao; Xiang Lin Zhao; Xiao Ye Yuan; Ping Gong
Journal:  Arch Pharm (Weinheim)       Date:  2006-11       Impact factor: 3.751

4.  Pyrazolo[1,5-a]pyrimidin-7-yl phenyl amides as novel anti-proliferative agents: parallel synthesis for lead optimization of amide region.

Authors:  Ariamala Gopalsamy; Hui Yang; John W Ellingboe; Hwei-Ru Tsou; Nan Zhang; Erick Honores; Dennis Powell; Miriam Miranda; John P McGinnis; Sridhar K Rabindran
Journal:  Bioorg Med Chem Lett       Date:  2005-03-15       Impact factor: 2.823

5.  Novel pyrazolopyrimidines as highly potent B-Raf inhibitors.

Authors:  Martin J Di Grandi; Dan M Berger; Darrin W Hopper; Chunchun Zhang; Minu Dutia; Alejandro L Dunnick; Nancy Torres; Jeremy I Levin; George Diamantidis; Christoph W Zapf; Jonathan D Bloom; YongBo Hu; Dennis Powell; Donald Wojciechowicz; Karen Collins; Eileen Frommer
Journal:  Bioorg Med Chem Lett       Date:  2009-10-28       Impact factor: 2.823

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.